Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 9 for:    N91115

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04600778
Recruitment Status : Not yet recruiting
First Posted : October 23, 2020
Last Update Posted : October 23, 2020
Sponsor:
Information provided by (Responsible Party):
GSNOR Therapeutics, Inc.

Brief Summary:

Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)

Detailed Description:To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment.

To investigate:

  1. The effect of cavosonstat compared with placebo, on the duration from baseline to first moderate AECOPD event
  2. The effect of cavosonstat compared with placebo, on respiratory function, as assessed by post-bronchodilator percent-predicted forced expiratory volume in one second (ppFEV1)
  3. The effect of cavosonstat compared with placebo on annualized rate of moderate AECOPD over 24 weeks of treatment
  4. The effect of cavosonstat compared with placebo on annualized rate of severe AECOPD over 24 weeks of treatment
  5. The safety and tolerability of cavosonstat compared with placebo
  6. The pharmacokinetics of cavosonstat
  7. Assessment of quality of life

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Other: placebo Drug: Cavosonstat 5 mg Drug: Cavosonstat 10 mg Drug: Cavosonstat 25 mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Estimated Study Start Date : February 3, 2021
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Placebo Comparator: placebo
twice daily
Other: placebo
placebo

Experimental: Cavosonstat 5 mg
twice daily
Drug: Cavosonstat 5 mg
Cavosonstat (low dose)

Experimental: Cavosonstat 10 mg
twice daily
Drug: Cavosonstat 10 mg
Cavosonstat (medium dose)

Experimental: Cavosonstat 25 mg
twice daily
Drug: Cavosonstat 25 mg
Cavosonstat (high dose)




Primary Outcome Measures :
  1. Annualized rate of moderate-to-severe acute exacerbations of COPD [ Time Frame: 24 weeks ]
    To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with moderate to severe COPD, who meet the following criteria (full details in main text):

    • Male or female aged between 40 and 75 years inclusive, at the time of informed consent
    • Patients with symptomatic COPD as defined by the 2019 GOLD diagnostic criteria
    • Post-bronchodilator (four puffs of albuterol) spirometry at screening demonstrating the following:

      1. FEV1/forced vital capacity (FVC) ratio of <0.70
      2. FEV1 ≥30% and FEV1 <80% of predicted normal
    • Current or prior history of ≥10 pack-years of cigarette smoking
    • Participants with COPD Assessment Test (CAT) score ≥10 at screening
    • Participants with a documented history of ≥1 moderate exacerbation within the year prior to screening
    • Participants with standard of care background therapy for three months and at a stable dose for at least one month, including either:
    • Single therapy: long-acting muscarinic agonist (LAMA), or
    • Double therapy: long-acting beta agonist (LABA) plus long-acting muscarinic agonist (LAMA) or inhaled corticosteroid (ICS) plus LABA or ICS plus LAMA, or
    • Triple therapy: LABA plus LAMA plus ICS
    • Meet the concomitant medication restrictions and continue to do so throughout the study
    • Have body mass index >21 kg/m2 and < 35 kg/m2
    • Males must agree not to donate sperm. They must be sexually abstinent or use a condom with all sexual partners. If the partner is of child-bearing potential, a condom with spermicide and a second reliable form of contraception must also be used
    • Females must be of non-childbearing potential, be sexually abstinent or use a highly effective form of contraception.
    • Able to sign an informed consent document

Exclusion Criteria:

  • Patients meeting any of the following criteria must be excluded from the study (full details in main text):

    • Patients with other respiratory disorders: current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, uncontrolled or unstable sleep apnea, cor pulmonale, clinically significant pulmonary hypertension or other active pulmonary diseases
    • Chest X-ray (or computerized tomography [CT] scan) reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD
    • Moderate or severe AECOPD within the previous four weeks
    • An upper or lower respiratory tract infection that required the use of antibiotics within the previous four weeks
    • Long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for more than 12 hours a day
    • Oral therapies for COPD (e.g. oral steroids, theophylline and roflumilast) or antibiotics or oral corticosteroid therapy within four weeks prior to screening
    • Prior history of, or planned pneumonectomy or lung volume reduction surgery
    • Participation in the acute phase of a pulmonary rehabilitation program within four weeks of screening or planned during the study
    • History of malignancy of any organ system within five years, except skin cancer which has been stable over one year and the investigator believes is no clinical significance.
    • Patients with uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant. This includes any hepatic disease or moderate to severe renal impairment.
    • Documented clinically significant cardiovascular disease such as: any history of arrhythmias, angina, recent (<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months prior to Screening.
    • Known or suspected history of alcohol or drug abuse within the last 5 years. Positive urine drug screen and blood alcohol level screen.
    • Clinically significant abnormal values for laboratory safety tests (hematology, blood chemistry, viral serology or urinalysis) at Screening, as determined by the Investigator.
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than twice the upper limit of normal.
    • Received an experimental drug within 30 days or five half-lives, whichever is longer.
    • Women who are pregnant or breast-feeding.
    • Prior exposure to a GSNOR inhibitor.
    • Major surgery (requiring general anesthesia) within 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
    • A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.
    • Any other reason that the Investigator considers makes the patient unsuitable to participate.
Layout table for additonal information
Responsible Party: GSNOR Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04600778    
Other Study ID Numbers: LVC-N91115-PS-II-01
First Posted: October 23, 2020    Key Record Dates
Last Update Posted: October 23, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases